垂体学会改良德尔菲共识:ACTH依赖性库欣综合征生物标志物的应用
多数专家报告使用深夜唾液皮质醇诊断轻度CS及监测垂体术后或药物、放疗后患者;共识认为恢复昼夜节律是CS的治疗目标。
要点
- 多数专家用深夜唾液皮质醇诊断轻度CS并用于术后或药物治疗后监测
- 多数专家认为周期性或重度CS可考虑阻滞-替代治疗
- 共识认为恢复昼夜节律是CS患者的治疗目标
核心结论
- 专家在ACTH依赖性CS诊断与监测的部分领域达成一致,结果旨在支持临床决策并提示未来研究优先方向
主要发现
- 第一轮31条声明中14条(45%)达成共识,第二轮25条声明中11条(44%)达成共识
- 多数专家报告使用深夜唾液皮质醇诊断轻度CS,并用于垂体手术后或药物、放疗后的监测
- 多数专家认为周期性或重度CS患者可考虑阻滞-替代治疗
- 共识认为恢复昼夜节律是CS患者的治疗目标
临床怎么用
- 临床可参考专家共识在轻度CS诊断及垂体术后、药物或放疗后监测中使用深夜唾液皮质醇
- 对周期性或重度CS可考虑阻滞-替代治疗
- 将恢复昼夜节律作为CS治疗目标之一
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Biochemical test results are central to clinical decision-making for the diagnosis and management of Cushing's syndrome (CS). With emerging research and increasing availability of different tests, updated consensus on the utility of these biomarkers is warranted. OBJECTIVE: To establish an updated consensus on the role of biomarkers in the diagnosis and monitoring of adrenocorticotropic hormone-dependent CS, address novel therapeutic approaches, and identify areas for future research. DESIGN: A modified two-round Delphi panel was conducted. Consensus was defined as ≥70% agreement/disagreement for Likert-scale statements or ≥70% selection of the same option for single-choice questions. SETTING: Participants represented a range of international expertise. PARTICIPANTS: Forty-one participants took part in the Delphi panel, with no attrition between rounds (one non-clinician was not required to complete the second round). An eight-member Steering Committee guided statement development. RESULTS: Of statements designed to reach consensus, 45% (14/31) and 44% (11/25) statements reached consensus in Rounds 1 and 2, respectively. Notably, most panelists reported the use of late-night salivary cortisol for diagnosis of mild CS and for monitoring following pituitary surgery or medical or radiation therapy. Most panelists responded that block-and-replace therapies can be considered in patients with cyclical or severe CS, and consensus was reached that restoration of circadian rhythm is a treatment goal for patients with CS. CONCLUSIONS: Areas of alignment among experts on the diagnosis and monitoring of CS are presented. The findings from this study are intended to support clinicians in their clinical decision-making and highlight priority areas for future research.
引用
- Fleseriu M, Biller BM, Bancos I, et al. Consensus on Biomarker Utility for ACTH-Dependent Cushing's Syndrome: A Pituitary Society Modified Delphi Panel. J Clin Endocrinol Metab. 2026. PMID: 42460773. doi:10.1210/clinem/dgag279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。